BioSpace News Archive

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth quarter and year-end 2022 financial results after the close of the market on Monday, March 6, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced that 12 studies containing newly discovered scientific and clinical data on the company’s knee and shoulder replacement solutions were presented at the 2023 Orthopaedic Research Society (ORS) annual meeting, on Feb. 10-14 in Dallas, Texas.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from four collaborative studies evaluating novel investigational combinations and strategies with the potential to target the HIV viral reservoir or enhance immune response to maintain virologic control in the absence of antiretroviral therapy (ART).

Aytu BioPharma, Inc. will report financial results for the quarter ended December 31, 2022, after the market close , Tuesday, February 21, 2023.

TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced the company will be participating in two upcoming investor conferences.

Accuray Incorporated announced its participation in the Cowen 43rd Annual Health Care Conference taking place March 6-8, 2022.

Olema Pharmaceuticals, Inc. announced that the Company will present at the following upcoming investor conferences:

Expanding Innovations, Inc., a spinal implant company that designs NON-SCREW based expandable cage technology, announced that the company has received 510 clearance from the FDA for the X-PAC Expandable Lateral Cage System.

THINK Surgical, a technology innovator developing orthopedic surgical robots, announced the appointment of Peter Verrillo as Chief Technology Officer.

AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2022.